10.6084/m9.figshare.c.3629294_D6.v1 Cedric Leroy Cedric Leroy Pedro Ramos Pedro Ramos Karen Cornille Karen Cornille Debora Bonenfant Debora Bonenfant Christine Fritsch Christine Fritsch Hans Voshol Hans Voshol Mohamed Bentires-Alj Mohamed Bentires-Alj Additional file 1: of Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition Springer Nature 2016 Phosphatidylinositol 3-kinase p110α p110β Resistance Breast cancer 2016-04-05 05:00:00 Journal contribution https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Activation_of_IGF1R_p110_AKT_mTOR_confers_resistance_to_-specific_PI3K_inhibition/4418579 is a figure showing BYL719 resistance in PIK3CA mutant breast cancer cells. A BYL719 resistance is reversible. BYL719 dose-response of parental and resistant lines (on or off BYL719 for 2 weeks) after 3 days of treatment. Cell numbers were evaluated using the sulforhodamide B assay. GI50 values were calculated using GraphPad Prism 6 software. Data are mean ± SEM (n >2). B pS6/S6 ratios in cells treated with DMSO or BYL719 (IC90) for 24 hours. Data are mean of pS6/S6 ratio ± SEM (n >3, *P <0.01). Immunoblots from three independent experiments have been quantified using the ImageJ software. (PDF 117 kb)